References
1. Cooke GS, Flower B, Cunningham E, et al. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update. Lancet Gastroenterol Hepatol. 2024;9(4):346-365. doi:10.1016/S2468-1253(23)00321-7
2. Crespo J, Cabezas J, Calleja JL, Buti M, Lazarus J V. The path to successful hepatitis C elimination in Spain. Nat Rev Gastroenterol Hepatol. 2023;20(11):689-690. doi:10.1038/S41575-023-00813-Z,
3. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. doi:10.1016/S2468-1253(22)00165-0/ATTACHMENT/FF8825CF-F77C-4606-8D97-DD6F0EBEDD47/MMC1.PDF
4. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. doi:10.1002/hep.29466
5. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018;155(6):1828-1837.e2. doi:10.1053/J.GASTRO.2018.08.024
6. Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51(7):728-736. doi:10.1111/apt.15660
7. Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: Results from a nationwide cohort. Gut. 2021;70(7):1375-1382. doi:10.1136/GUTJNL-2020-322786,
8. Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes, Obes Metab. 2022;24(S2):28-43. doi:10.1111/DOM.14484,
9. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691-702. doi:10.1136/GUTJNL-2023-330595
10. Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet (London, England). January 2021. doi:10.1016/S0140-6736(21)01701-3
11. Ferrari AJ, Santomauro DF, Aali A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England). 2024;403(10440):2133-2161. doi:10.1016/S0140-6736(24)00757-8
12. Allen AM, Younossi ZM, Diehl AM, Charlton MR, Lazarus J V. Envisioning how to advance the MASH field. Nat Rev Gastroenterol Hepatol. 2024;21(10). doi:10.1038/S41575-024-00938-9,
13. Lazarus J V., Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1). doi:10.1038/S41575-021-00523-4
14. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5. doi:10.1053/j.gastro.2015.04.005
15. Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. October 2024. doi:10.1097/HEP.0000000000001112
16. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. April 2025. doi:10.1056/NEJMOA2413258
17. Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet (London, England). 2024;404(10464):1761-1778. doi:10.1016/S0140-6736(24)01811-7,
18. Escalada J. Drug approach to treatment for obesity in adults: perspectives and considerations. Rev Esp Enferm Dig. 2024 Jul;116(7):353-355. doi: 10.17235/reed.2024.10206/2023
19. Mingrone G, Rajagopalan H. Bariatrics and endoscopic therapies for the treatment of metabolic disease: Past, present, and future. Diabetes Res Clin Pract. 2024;211. doi:10.1016/j.diabres.2024.111651
20. Farha J, Abbarh S, Haq Z, et al. Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope? Curr Gastroenterol Rep. 2020;22(12). doi:10.1007/S11894-020-00798-8,
21. Jirapinyo P, Hadefi A, Thompson CC, et al. American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity. Gastrointest Endosc. 2024;99(6):867-885.e64. doi:10.1016/j.gie.2023.12.004
22. Matteo MV, Gualtieri L, Bove V, et al. Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease. Expert Rev Gastroenterol Hepatol. 2024;18(8):397-405. doi:10.1080/17474124.2024.2387231,
23. Jirapinyo P, Jaroenlapnopparat A, Zucker SD, Thompson CC. Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD. Obes Surg. 2024;34(5):1471-1478. doi:10.1007/S11695-024-07178-5,
24. Abad J, Llop E, Arias-Loste MT, et al. Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicentre, Sham-controlled, Randomized Trial. Clin Gastroenterol Hepatol. December 2024. doi:10.1016/J.CGH.2024.10.027
25. AEEH. Plan Nacional Salud Hepatica 2032. https://aeeh.es/wp-content/uploads/2024/02/AEEH-Plan-Nacional-Salud-Hepaitica.pdf. Accessed January 26, 2025.
26. Downer S, Berkowitz SA, Berkowitz SA, Harlan TS, Olstad DL, Mozaffarian D. Food is medicine: actions to integrate food and nutrition into healthcare. BMJ. 2020;369. doi:10.1136/BMJ.M2482
27. Paik JM, Duong S, Zelber-Sagi S, Lazarus J V., Henry L, Younossi ZM. Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction-Associated Fatty Liver Disease Among Adolescents in the United States. Am J Gastroenterol. 2024;119(6):1089-1101. doi:10.14309/AJG.0000000000002749
28. Kardashian A, Dodge JL, Terrault NA. Food Insecurity is Associated With Mortality Among U.S. Adults With Nonalcoholic Fatty Liver Disease and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2022;20(12):2790-2799.e4. doi:10.1016/J.CGH.2021.11.029
29. Younossi ZM, Zelber-Sagi S, Kuglemas C, et al. Association of food insecurity with MASLD prevalence and liver-related mortality. J Hepatol. 2025;82(2). doi:10.1016/J.JHEP.2024.08.011